Understanding What Percentage of People Don’t Lose Weight on Ozempic

Last reviewed: July 7, 2026

Last updated: July 7, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide, the active ingredient in Ozempic, helps most people lose weight by reducing appetite and regulating blood sugar. However, clinical data shows that 10-15% of patients experience little to no weight loss despite consistent use and proper dosing.

Why Do Some People Not Lose Weight on Semaglutide?

Treatment resistance to GLP-1 medications occurs for several interconnected reasons. Your body's unique genetic makeup influences how well you respond to appetite-suppressing hormones and how your metabolic pathways function. Additionally, factors like medication adherence, underlying metabolic conditions, insulin resistance severity, and lifestyle choices all affect whether semaglutide produces meaningful results.

Research from major obesity studies demonstrates that while 85-90% of people lose at least 5% of their body weight on semaglutide, the remaining 10-15% see minimal changes. This variation isn't due to personal failure—it reflects real biological differences in how different bodies process and respond to this medication class.

Genetic Factors That Influence GLP-1 Response

Your genes control the production and function of GLP-1 receptors throughout your digestive system and brain. Specific genetic variants in the GLP1R gene, GIPR gene, and FTO gene determine how sensitive your body is to semaglutide's effects. Someone carrying a less responsive variant may require a different medication strategy or combination therapy to achieve weight loss.

The MC4R gene also plays a critical role in hunger signaling and metabolic regulation. Variations in this gene can mean that GLP-1 alone doesn't fully suppress appetite signals in your brain, even at higher doses. PlexusDx maps these genetic pathways through the Precision Peptide Genetic Test, which identifies which of 14 metabolic pathways and 49 peptides drive your weight regulation.

When to Consider Switching to Tirzepatide or Dual Therapy

If you've been on semaglutide for 8-12 weeks at therapeutic doses without meaningful weight loss, your healthcare provider may recommend tirzepatide, which works on two hormone receptors instead of one. Tirzepatide targets both GLP-1 and GIP pathways, making it effective for people who don't respond adequately to single-pathway therapy. PlexusDx offers Compounded Tirzepatide Injection at $289/mo month-to-month, or from $249/mo on the 6-month plan, with your dose potentially increasing while your price remains flat.

Another option is GLP-Squared Injection, a dual compound combining both semaglutide and tirzepatide in one injection. This approach activates multiple metabolic pathways simultaneously, offering superior results for treatment-resistant patients. Starting at $249/mo, GLP-Squared targets a broader spectrum of appetite and metabolic signaling mechanisms.

Personalizing Your Weight Loss Treatment With Genetic Insights

One-size-fits-all medication approaches often fail because they ignore your individual genetic blueprint. The Precision Peptide Genetic Test ($99 add-on after your first month) reveals which peptide pathways drive your metabolism, allowing PlexusDx to recommend the most effective compound and dosing strategy for your biology. Testing identifies variants in key genes like GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313.

With genetic guidance, patients who previously failed on semaglutide alone often succeed by switching to tirzepatide, oral formulations, or combination protocols. PlexusDx serves all 50 states through licensed 503A compounding pharmacies with no insurance required, HSA/FSA eligibility, and transparent flat pricing—meaning your dose can increase while your monthly cost stays the same.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What percentage of people fail to lose weight on Ozempic?

Approximately 10-15% of people on semaglutide experience minimal weight loss despite proper use. This treatment resistance is driven by genetic variation, not by personal failure or non-compliance. PlexusDx can help identify why you're not responding and recommend an alternative strategy.

How long should I take Ozempic before knowing if it's working?

Most clinical guidelines suggest waiting 8-12 weeks at a therapeutic dose to evaluate response. If you haven't lost at least 5% of your starting body weight by this point, it's reasonable to discuss alternatives with your provider. Starting sooner on a more effective medication may save you time and frustration.

Is tirzepatide better than semaglutide for weight loss?

Tirzepatide activates two metabolic pathways (GLP-1 and GIP) versus semaglutide's one, making it more effective for many patients. Clinical trials show tirzepatide users lose 1.5 to 2 times more weight than semaglutide users on average. PlexusDx Compounded Tirzepatide Injection is $289/mo month-to-month (or $249/mo on the 6-month plan), flat pricing with dose flexibility.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

Yes. The PlexusDx Precision Peptide Genetic Test examines 14 metabolic pathways and 49 peptides to identify your unique response profile. Testing costs $99 and reveals whether you carry variants that reduce GLP-1 sensitivity, helping clinicians choose semaglutide, tirzepatide, dual therapy, or other protocols most likely to work for your genetics.

What are PlexusDx pricing and access requirements?

PlexusDx Semaglutide Injection is $189/mo month-to-month (or $149/mo on the 6-month plan) flat (no per-dose increases), with HSA/FSA eligibility and service in all 50 states. No insurance required, no membership fees. Medications come from licensed 503A compounding pharmacies, ensuring quality and safety. Your dose may increase, but your price won't.

Related Reading

• Why Do Some People Tolerate Dairy While Others Don T Is It Genetic
• Ozempic For Losing Weight
• Ozempic For Weight Loss 2
• Average Weight Loss On Ozempic

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.